Compared with chemotherapy, many targeted agents have been developed to improve the typically dismal outcome associated with NSCLC, especially small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for its capability of crossing the BBB. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.